metricas
covid
Buscar en
Medicina Clínica Práctica
Toda la web
Inicio Medicina Clínica Práctica Amiodarone-induced thyrotoxicosis refractory to medical therapy: A case report
Información de la revista
Vol. 2. Núm. 4.
Páginas 73-76 (julio - agosto 2019)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
2086
Vol. 2. Núm. 4.
Páginas 73-76 (julio - agosto 2019)
Clinical report
Open Access
Amiodarone-induced thyrotoxicosis refractory to medical therapy: A case report
Tirotoxicosis por amiodarona refractaria a terapia médica: a propósito de un caso
Visitas
2086
Francisco Javier Gómeza,
Autor para correspondencia
kikosevi76@icloud.com

Corresponding author.
, Paloma Gónzaleza, Rocío Juárezb, Virgilio Martínezc, Manuel José Fernándezc, Cristina Contrerasa, Alvaro García-Manzanaresa
a Servicio de Endocrinología y Nutrición, Hospital General La Mancha Centro, Alcázar de San Juan (Ciudad Real), Spain
b Servicio de Anatomía Patológica, Hospital General La Mancha Centro, Alcázar de San Juan (Ciudad Real), Spain
c Servicio de Cardiología, Hospital General La Mancha Centro, Alcázar de San Juan (Ciudad Real), Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (4)
Mostrar másMostrar menos
Tablas (2)
Table 1. Comparison between amiodarone-induced thyrotoxicosis type 1 and type 2.1,3,7
Table 2. Free T3, free T4, TSH and thyroid antibodies values during hospitalization.
Mostrar másMostrar menos
Abstract

Amiodarone is a potent class III antiarrhythmic drug used for both supra and ventricular tachyarrhythmias. Due to its high iodine content and similar structure to thyroxine (T4) and triiodothyronine (T3), abnormalities in thyroid function are common (hyper/hypothyroidism) in patients taking amiodarone, especially with long term use. We present the case of a patient with amiodarone-induced thyrotoxicosis (AIT), refractory to medical therapy, which required total thyroidectomy for symptomatic control.

Keywords:
Amiodarone-induced thyrotoxicosis
Hyperthyroidism
Total thyroidectomy
Resumen

La amiodarona es un potente antiarrítmico clase III, indicada en el tratamiento de taquiarritmias supra y ventriculares. Debido a su alto contenido en yodo y estructura similar a la tiroxina (T4) y triyodotironina (T3), son frecuentes las alteraciones en la función tiroidea (hiper/hipotiroidismo) en pacientes que la consumen. Presentamos el caso de un paciente con tirotoxicosis inducida por amiodarona (TIA), refractaria a terapia médica, que precisó tiroidectomía total para control sintomático.

Palabras clave:
Tirotoxicosis inducida por amiodarona
Hipertiroidismo
Tiroidectomía total
Texto completo
Introduction

Amiodarone is a potent class III antiarrhythmic drug used for both supra and ventricular tachyarrhythmias, with a high iodine content (37.5% of its mass),1,2 and it has a similar structure to thyroxine (T4) and triiodothyronine (T3), which is translated in a high rate of thyroid dysfunctions (15–20%).3,4 Amiodarone-induced thyrotoxicosis (AIT) typically occurs in iodine-deficient areas of the world.5,6 In Europe, amiodarone-induced thyroid dysfunction affects 3 over 100 treated patients per year, and AIT is the major form.7 The differential diagnoses of AIT are classified as type 1 and type 2. Type 1 AIT is more likely to occur in subjects with underlying thyroid pathology as a direct effect of the iodide load from the amiodarone therapy. Type 2 AIT is caused by direct toxic effect of amiodarone, which causes a destructive thyroiditis and it typically occurs in patients without underlying thyroid disease (see Table 1). Sometimes, in the same subject, both mechanisms can be present.1,3,8 Amiodarone is very lipophilic and it has a long elimination half-life (107 days), mainly due to its storage in adipose tissue, and its toxic effects may persist or even occur several months after its discontinuation.1,8,9 We present the case of a patient with Type 2 AIT, who failed to respond to therapy medical conventional, and total thyroidectomy was performed as permanent solution.

Table 1.

Comparison between amiodarone-induced thyrotoxicosis type 1 and type 2.1,3,7

  Type 1  Type 2 
Preexisting or latent thyroid disease  Usually present  Absent 
Prevalence  More common in iodine-deficient areas  More common in iodine-replete areas 
Duration of amiodarone intake  Usually shorter (<1–2yrs)  Usually longer (>2yrs) 
Pathogenesis  Excess hormone synthesis  Excess release of preformed hormone 
Thyroid examination  Goiter more likely to be present  Normal or tender thyroid gland 
Thyroid autoantibodies  More likely to be present  Likely absent 
Radioactive iodine uptake Scan  Increased uptake (>30%)  <1% 
Sesta-MIBI uptake scan  Normal  Absent 
Color-flow Doppler sonography  Increased  Normal or decreased 
Interleukin-6  Normal  High 
Treatment  Thionamides, perchlorate or lithium  Glucocorticoids 
Case presentation

Our patient is a 67-year-old white man with history of hypertension, lipid disorder and atrial fibrillation (AF), who developed minimal effort dyspnea secondary to AF with rapid ventricular rate. One month earlier, he had been diagnosed from amiodarone induced thyrotoxicosis and had stopped amiodarone therapy. In addition, therapy with methimazole (20mg/day) and oral prednisone tapered dose had been started.

On admission, he was hemodynamically stable and afebrile. Physical examination revealed warm and sweaty skin; no palpable or visible goiter and no signs or symptoms for thyroid-associated orbitopathy were found. The auscultation showed irregular heartbeat and bibasilar crackles. Furthermore, he related unexplained weight loss of 5% of body weight over the last two or three months.

Complementary tests

ECG: AF with a rate of 115bpm. 0° axis. Flattened T waves in anterior and lateral leads.

Echocardiogram: The left ventricular internal size is increased. Left ventricular ejection fraction is >55% by visual estimation. Left atrium is not dilated. No evidence of valvular heart disease.

Thyroid ultrasound: The thyroid gland is normal in size and echogenicity. There are no discrete nodules evident. No lower cervical lymphadenopathy. Color-Doppler showed decreased blood flow.

Admission laboratory tests confirmed thyrotoxicosis (see Table 2). Thyroid autoantibodies were within the normal range (see Table 2). Hemogram and biochemical parameters, including cardiac markers (troponin and creatine phosphokinase) did not show significant alterations.

Table 2.

Free T3, free T4, TSH and thyroid antibodies values during hospitalization.

  fT3N [2.57–4.43]pg/mL  fT4N [0.93–1.78]ng/dL  TSHN [0.27–4.24]μUI/mL  TPOAbaN [0–34]UI/mL  TgAbaN [10–115]UI/mL 
−10 days (on admission)  32.6  >7.77  0.01  11  18 
−1 week  5.83  7.64  0.01     
Surgery  4.52  4.65  0.01     
3 days  3.48  3.76  0.01     
1 week  1.21  1.67  0.01     
4 weeks  –  0.8  0.86     
a

TPOAb: anti-thyroperoxidase antibodies; TgAb: anti-thyroglobulin antibodies.

Scintigraphy was not performed, since this test which is not available in our center, and the patient's clinical status would not make it possible.

Treatment, outcome and follow-up

Initially, medical therapy was intensified with high dose of anti-thyroid drugs (methimazole 40mg/day), intravenous steroids (methylprednisolone 60mg/day) and propranolol (100mg/day), adopting a rate control strategy for his atrial fibrillation. Good clinical response was shown on first instance, specially dyspnea symptoms and heart palpitations.

Three days later, the patient presented a clinical worsening, he reported increasing fatigue, fever and palpitations. Heart acute failure was diagnosed due to difficult-to-control atrial fibrillation and he was started on digoxin and loop diuretics. Moreover, methimazole was stopped and therapy with propylthiouracil (PTU) was started, as it interferes with the conversion of T4–T3. Propranolol was changed to Atenolol, as it is a cardioselective beta-blocker. Taking into account the clinical-analytical worsening, surgical intervention was pursued (total thyroidectomy) and potassium perchlorate was added to treatment, which minimizes intrathyroid iodine content by competitively inhibiting thyroidal iodine intake. Until surgery, the patient remained hemodynamically stable, but he continued to have evening fevers due to thyrotoxicosis, discarding any underlying infection.

Ten days after admission, total thyroidectomy was performed. The patient's intra- and postoperative course was unremarkable. The patient was clinically and biochemically euthyroid one week after the thyroidectomy (see Table 2 and Fig. 1). Replacement doses of levothyroxine were subsequently started (50mcg/day) and were discharged from hospital.

Fig. 1.

Free T3 and free T4 values during hospitalization.

(0.06MB).

One month after surgery, we did a follow-up visit and the patient remained clinically asymptomatic. Replacement dose of levothyroxine was adjusted (100mcg/day), according to the levels of free T4, which were low (see Table 2 and Fig. 1). Digoxin was discontinued on cardiology follow-up consultation due to slight bradycardia on ECG.

Discussion

We present a case of type 2 AIT refractory to glucocorticoids and high dose of anti-thyroids drugs. The patient was suspected of having “mixed thyrotoxicosis”, since thyroid antibodies were within the normal range and no response to glucocorticoids was shown. However, final pathology report revealed follicles exhausted enlarged with flattened surface epithelium, vacuolated cytoplasm and pyknotic nucleus. Aggregates of foamy histiocytes were found within the injured follicles, as well as in the adjacent interstitium (see Figs. 2–4). These changes are typical for amiodarone-induced thyroid injury and it can be classified as type 2 AIT, since there was no evidence of latent thyroid disease.10

Fig. 2.

There are follicles enlarged with lining epithelium flattened, and follicles exhausted (H/E).

(0.17MB).
Fig. 3.

The epithelium in many of the follicles is degenerated or partially denuded, with vacuolated cytoplasm and pyknotic nuclei. Aggregates of foamy histiocytes within the injured follicles (H/E).

(0.15MB).
Fig. 4.

There are follicles enlarged with flattened surface epithelium, and some macrophage into the parenchyma (H/E).

(0.11MB).

Treatment of AIT depends on the type as well as the severity of thyrotoxicosis on presentation, but it usually responds to medical therapy, especially if it is an type 2 AIT.3,8,10 Severe AIT, like our case, requires more urgent intervention. Sometimes, an association of thionamides, perchlorate and glucocorticoids is necessary to control severe thyrotoxicosis.8,11,12 Alternative treatments with lithium or iopanoic acid have been described, but with low evidence.3

In our patient, in spite of medical management with thionamides and glucocorticoids, left heart failure was diagnosed, and surgical treatment was required. In the event of worsening thyrotoxicosis in spite of medical management, total or near-total thyroidectomy may be warranted.13–15 There have been over 100 reported cases of total thyroidectomy for AIT.16 Most are performed under general anesthesia with surprisingly low morbidity and mortality.14,16 There are also case reports of minimally invasive thyroidectomy being performed under local anesthesia, but this surgical procedure is not very common.17

Conclusion

Amiodarone commonly causes thyroid dysfunction. It is recommended that patients are taking amiodarone be screened with TSH levels periodically. Most cases of AIT are amenable to medical therapy with thionamides and/or glucocorticoids. In those patients who do not respond to these measures or are too critically ill to allow for a long enough course of medical management, thyroidectomy is a viable therapeutic option.

Conflict of interests

The authors declare no conflict of interests.

References
[1]
A.B. Winter Tavares, S. Kalil de Paula, M. Vaisman, F. Teixeira Pde.
Amiodarone and thyrotoxicosis: case reports.
Arq Bras Cardiol, 95 (2010), pp. e122-e124
[2]
J. Gesing, J. Hoppmann, R. Gebauer, R. Pfäffle, A. Bertsche, W. Kiess.
Diagnosis and clinical course of three adolescents with amiodarone-induced hyperthyroidism.
Pediatr Cardiol, 39 (2018), pp. 1707-1716
[3]
F. Bogazzi, L. Bartalena, E. Martino.
Approach to the patient with amiodarone-induced thyrotoxicosis.
J Clin Endocrinol Metab, 95 (2010), pp. 2529-2535
[4]
A. Khan, A. Puttanna, D. Raskauskiene.
Amiodarone-induced thyrotoxicosis type 1 or type 2?.
[5]
M.L. Tanda, E. Piantanida, A. Lai, L. Liparulo, L. Sassi, F. Bogazzi, et al.
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association.
Clin Endocrinol (Oxf), 61 (2004), pp. 494-502
[6]
L. Bartalena, W.M. Wiersinga, M.L. Tanda, F. Bogazzi, E. Piantanida, A. Lai, et al.
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists.
Clin Endocrinol (Oxf), 69 (2008), pp. 812-818
[7]
S. Ahmed, I.C. Van Gelder, A.C. Wiesfeld, D.J. Van Veldhuisen, T.P. Links.
Determinants and outcome of amiodarone-associated thyroid dysfunction.
Clin Endocrinol (Oxf), 75 (2011), pp. 388-394
[8]
S. Maqdasy, T. Benichou, S. Dallel, B. Roche, F. Desbiez, N. Montanier, et al.
Issues in amiodarone-induced thyrotoxicosis: update and review of the literature.
Ann Endocrinol (Paris), 80 (2018), pp. 54-60
[9]
S. Basaria, D.S. Cooper.
Amiodarone and the thyroid.
Am J Med, 118 (2005), pp. 706-714
[10]
I. Kosuke, S. Jun, T. Kondo, M. Kaoru, S. Chiho, T. Yuya, et al.
Amiodarone-induced thyrotoxicosis with cardiopulmonary arrest.
[11]
M. Safran, E. Martino, F. Aghini-Lombardi, L. Bartalena, S. Balzano, A. Pinchera, et al.
Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.
J Endocrinol Investig, 9 (1986), pp. 201-207
[12]
L.J. Reichert, H.A. de Rooy.
Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment.
BMJ, 298 (1989), pp. 1547-1548
[13]
M. Batori, M. Nardi, E. Chatelou, A. Straniero, M. Makrypodi, M. Ruggieri.
Total thyroidectomy in amiodarone-induced thyrotoxicosis. Preoperative, intraoperative and postoperative considerations.
Eur Rev Med Pharmacol Sci, 10 (2006), pp. 187-190
[14]
A. Kotwal, J. Clark, M. Lyden, T. McKenzie, G. Thompson, M.N. Stan.
Thyroidectomy for amiodarone-induced thyrotoxicosis: Mayo Clinic experience.
J Endocr Soc, 2 (2018), pp. 1226-1235
[15]
L. Bartalena, F. Bogazzi, L. Chiovato, A. Hubalewska-Dydejczyk, T.P. Links, M. Vanderpump.
2018 European Thyroid Association (ETA) Guidelines for the management of amiodarone-associated thyroid dysfunction.
Eur Thyroid J, 7 (2018), pp. 55-66
[16]
J. Gough, I.R. Gough.
Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease.
World J Surg, 30 (2006), pp. 1957-1961
[17]
P. Berti, G. Materazzi, F. Bogazzi, C.E. Ambrosini, E. Martino, P. Miccoli.
Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study.
Langenbeck's Arch Surg, 392 (2007), pp. 709-713
Copyright © 2019. The Authors
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos